Amylin CEO on Diabetes & Diet Drugs

Previous Video: What CIT Bankruptcy Means for Small Biz
Next Video: RBS, Lloyds Face Restructuring

Airtime: ET

The FDA has approved Amylin's Byetta as a stand-alone diabetes drug. The company's CEO, Daniel Bradbury, discusses the approval and more with CNBC's Mike Huckman.

Previous Video: What CIT Bankruptcy Means for Small Biz
Next Video: RBS, Lloyds Face Restructuring

TOP VIDEO

Word on the Street
The rumors and the mood on Wall Street, with with Alan Valdes, Hilliard Lyons.

Paul: Audit the Fed

Why the push to regulate the Fed more tightly, with Rep. Ron Paul (R-TX) and member of Financial Services Committee; James Reynolds, Loop Capital Markets; and CNBC's Rick Santelli, Steve Liesman, Joe Kernen & Becky Quick.

LATEST VIDEO

Data is a real-time snapshot *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc. All Rights Reserved.
A Division of NBC Universal

Amylin CEO on Diabetes & Diet Drugs

More Videos from CNBC

TOP VIDEO

LATEST VIDEO